newsfilter
← Latest News
PR Newswire·

Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference

  • Protalix BioTherapeutics, Inc. announced that CEO Dror Bashan will present at the Stifel 2026 Healthcare Conference in New York City on November 10-12, 2026.
  • Mr. Bashan's live corporate overview is scheduled for Tuesday, November 10, at 2:00 p.m. Eastern Time in the Hubbard Room, Fifth Floor.
  • The company's management will hold one-on-one meetings with registered investors, which must be arranged through a Stifel representative.
  • A live webcast of the presentation is available at a provided URL & will also be posted on the Investors section of www.protalix.com, with an archived replay following the event.
  • Protalix manufactures two enzyme replacement therapies using its proprietary ProCellEx plant cell-based expression system, which has received FDA approval.
  • The company has licensed worldwide rights to its drug taliglucerase alfa (Elelyso) to Pfizer Inc., excluding Brazil where Protalix retains full rights.
  • Protalix partners with Chiesi Farmaceutici S.p.A. for the global development & commercialization of Elfabrio, approved by the FDA & EMA in May 2023.
  • The company's pipeline includes PRX-115 for uncontrolled gout & PRX-119 for NETs-related diseases.
  • Investor inquiries can be directed to Mike Moyer of LifeSci Advisors.